On the other hand, pharmacological modulation or CRISPR‐mediated KD of HRH1 did not induce significant effects on chemosensitivity or basal differentiation state, while histamine induced only a moderate reduction in clonogenic capacity, thus precluding the therapeutic potential of HRH1 targeting in myeloid malignancies and further supporting a minor role of HRH1, in line with previous results.5 This evidence concerns the gene HRH1 and myeloid neoplasm.